Estimated longevity benefit: +1.0 years. Evidence score: 64/100.
Acarbose is an alpha-glucosidase inhibitor that slows the breakdown of complex carbohydrates to blunt post-meal glucose and insulin spikes. By reducing the cumulative metabolic burden and insulin signaling, it addresses a primary driver of aging and has demonstrated up to 22% median lifespan extension in rigorous animal testing.